Search clinical trials for: Purinergic P2 Receptor Antagonists

Total 9463 results

Gordon Bernard
AstraZeneca

Terminated

Ticagrelor in Severe Community Acquired Pneumonia (TCAP)

Community Acquired Pneumonia, Severe

United States
Kowa Research Institute, Inc.

Completed

Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers

Healthy

United States
General Hospital of Chinese Armed Police Forces

Completed

Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI

Non ST Segment Elevation Acute Coronary Syndrome

China
Daewoong Pharmaceutical Co. LTD.

Unknown

Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease

MCA - Middle Cerebral Artery Dissection

Korea, Republic of
AstraZeneca

Completed

Clopidogrel Bioequivalence Study in Healthy Subjects

Bioequivalence, AUC, Cmax, Pharmacokinetics

Germany
Emory University

Completed

Investigation of the Athero-Protective Effects of Clopidogrel (APECS)

Coronary Artery Disease

United States
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions

Fasting

India
Assistance Publique - Hôpitaux de Paris

Completed

Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects

Healthy

France
Sanofi
Bristol-Myers Squibb

Completed

Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)

Blood Platelet Disorders | Congenital Heart Defects

United States, France, Canada, Germany, Italy, Belgium
University Hospital, Bordeaux
Ministry for Health and Solidarity, France

Recruiting

Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk (PSSIT)

Systemic Sclerosis | Scleroderma

France
Tabula Rasa HealthCare

Active, not recruiting

Type 2 Diabetes With Antiplatelet Drugs

Myocardial Infarction | Heart Failure | Type2 Diabetes | Antiplatelet Drugs

United States
Aurora Health Care

Completed

Chewed Versus Integral Pill of Ticagrelor

Percutaneous Coronary Intervention

United States
University of Virginia
AstraZeneca

Completed

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

End Stage Renal Disease | Vascular Access Patency

United States
The University of The West Indies

Completed

The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease (TWIST)

Platelet Dysfunction Due to Drugs

Trinidad and Tobago
J.M. ten Berg
AstraZeneca

Unknown

The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (POPular CABG)

Coronary Artery Disease | Acute Coronary Syndrome | Stable Angina

Netherlands
IHF GmbH - Institut für Herzinfarktforschung

Completed

Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes (Real-TICA)

Acute Coronary Syndrome (ACS)

Germany
AstraZeneca

Completed

A Pharmacodynamic Study With Ticagrelor in African American Patients

Stable Coronary Artery Disease

United States
AstraZeneca

Completed

Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers

Healthy

Japan
Hospital Universitario Dr. Jose E. Gonzalez

Terminated

Comparative Bioavailability Study of Two Oral Formulations of Clopidogrel

Comparative Bioavailability of Clopidogrel Tablets

Mexico
University Hospital, Angers

Unknown

Platelets Induced Vasodilation, in Vitro and in Vivo Study

Peripheral Arterial Disease

France
Portola Pharmaceuticals

Completed

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI (INNOVATE-PCI)

Percutaneous Coronary Intervention

United States, Austria, Canada, Germany, Poland
AstraZeneca
Iqvia Pty Ltd

Withdrawn

Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. (HESTIA5)

Sickle Cell Disease
Janssen-Cilag International NV

Completed

A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739

Healthy

Belgium
Daiichi Sankyo, Inc.

Completed

Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects

Drug Interaction

United Kingdom
University of Kentucky

Completed

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor (XANTHIPPE)

Pneumonia | Acute Lung Injury | Community Acquired Pneumonia | Hospital Acquired Pneumonia

United States
Zealand University Hospital

Terminated

RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders (RISCLON)

Stroke

Denmark
AstraZeneca

Completed

Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers

Drug Drug Interaction

United States, Sweden
Accumetrics, Inc.

Completed

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety (GRAVITAS)

Acute Coronary Syndrome | Coronary Arteriosclerosis

United States, Canada
Vastra Gotaland Region
Sahlgrenska University Hospital, Sweden

Recruiting

Ticagrelor Monotherapy After Stenting (TIMO)

Acute Myocardial Infarction

Sweden
Liverpool University Hospitals NHS Foundation Trust
Liverpool Heart and Chest Hospital NHS Foundation Trust; Countess of Chester... and other collaborators

Completed

The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome (ROBOT-ACS)

Bleeding | Acute Coronary Syndrome | Ticagrelor | Clopidogrel | Novel Anti-platelets

United Kingdom
First Affiliated Hospital of Harbin Medical University

Completed

Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients

Inflammation | Thrombosis
AstraZeneca

Completed

ADHERE-S (NIS Brilique)

ACS (Acute Coronary Syndrome)

Serbia
Chinese University of Hong Kong

Completed

Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding

Gastrointestinal Bleeding

China
Icahn School of Medicine at Mount Sinai
Doris Duke Charitable Foundation

Completed

Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?

Clopidogrel

United States
Sheba Medical Center

Completed

Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study

Non ST Elevation Myocardial Infarction | Acute Coronary Syndromes

Israel
Sanofi
Bristol-Myers Squibb

Completed

Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects

Healthy

United States, France
Sanofi
Bristol-Myers Squibb

Completed

Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects

Healthy

Germany
Deutsches Herzzentrum Muenchen
Technical University of Munich

Completed

75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)

Coronary Disease

Germany
Federico II University

Recruiting

Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention (MIRACOR)

Coronary Artery Disease

Italy
Yonsei University

Not yet recruiting

Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass

Multi Vessel Coronary Artery Disease

Korea, Republic of
University of Florida
Scott R. MacKenzie Foundation

Completed

Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

Coronary Artery Disease (CAD) | Type 2 Diabetes Mellitus (T2DM) | Chronic Kidney Disease (CKD)

United States
University of Florida
AstraZeneca

Completed

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI (OPTIMUS-6)

Coronary Artery Disease | Diabetes Mellitus, Type 2

United States
Medical University of Warsaw
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Completed

Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction (AFFECT EV)

Myocardial Infarction

Netherlands, Poland
AORTICA Group

Completed

Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI (COMPARE)

ST Elevation Myocardial Infarction

Spain
The Medicines Company

Completed

Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation (AMPHORE)

Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

France
Federal University of São Paulo

Completed

Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis (SAMPA)

Acute Coronary Syndrome | Platelet Function

Brazil
Unity Health Toronto
Prairie Vascular Research Inc.

Completed

Ticagrelor for PCI Post Thrombolysis (SETFAST)

Acute Myocardial Infarction

Canada
Michael Wolzt, Prof. MD

Completed

The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment

Ischemia

Austria
Deutsches Herzzentrum Muenchen

Unknown

Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing (ISAR ADAPT PF)

Coronary Heart Disease

Germany, Hungary
University of Patras

Completed

Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Platelet Reactivity

Greece

3

Subscribe